{
  "id": 1525270,
  "title": "Freedom Broker raises Candel Therapeutics stock price target on trial progress",
  "url": "https://urgent.news/2026/08/17/freedom-broker-raises-candel-therapeutics-stock-price-target-on-trial",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-17T17:10:50.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/freedom-broker-raises-candel-therapeutics-stock-price-target-on-trial-progress-93CH-4863757"
  },
  "original_language": "en",
  "account": "Freedom Broker has increased its price target for Candel Therapeutics Inc. (CADL) to $15.00 from $14.00, maintaining a Buy rating on the stock. The current trading price stands at $12.16, up 107% year-to-date and nearing its 52-week high of $11.95. The company cites the commencement of patient enrollment in the global Phase III AURORA trial for CAN-2409 in non-small cell lung cancer as a significant development. PUBONI data reveals the firm's heightened confidence in the drug's approval prospects following the release of pivotal Phase III data.\n\nCandel Therapeutics has confirmed plans to file a Biologics License Application for CAN-2409 in localized prostate cancer by the fourth quarter of 2026, with a potential commercial launch anticipated in 2027. Despite operating expenses exceeding estimates, the company maintains a strong financial position, as evidenced by its robust current ratio of 16.09 and ample cash reserves exceeding its debt. This outlook supports the company's development timeline through the planned 2027 launch.\n\nThe enhanced price target reflects the substantial potential of CAN-2409 and its sibling CAN-3110 in oncology. Candel Therapeutics recently appointed Mark Sims as Chief Commercial Officer, effective July 6, 2026, to spearhead the commercial strategy for aglatimagene besadenovec in prostate cancer. Additionally, the company has renewed the employment agreement with CFO Charles Schoch, maintaining his position with an annual base salary of $468,600 and potential bonuses.\n\nIndustry analysts show confidence in Candel Therapeutics, with H.C. Wainwright maintaining a Buy rating and raising the target price to $23, while Stifel initiated coverage with a Buy rating and a $22 price target. Both firms have highlighted the potential commercial trajectory of aglatimagene as a viral immunotherapy, emphasizing its clinical validation in solid tumor settings. These developments underscore the ongoing advancements and strategic planning within Candel Therapeutics as it navigates its clinical trials and prepares for future product launches.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}